Friday, April 5, 2019

Trovagene Gets $1.5M In PIPE For Oncology Drug Efforts

San Diego-based oncology therapeutics developer Trovagene, which is publicly listed on the Nasdaq as TROV, said it has received a $1.5M, private placement. The new investment came from Lincoln Park Capital. According to Trovagene, the new funding will go towards advancing three of its clinical development programs. Lincoln Park Capital is an existing i

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.